{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:31Z","timestamp":1786118911226,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1097\/jcp.0b013e318172b45f","type":"journal-article","created":{"date-parts":[[2008,5,9]],"date-time":"2008-05-09T03:06:01Z","timestamp":1210302361000},"page":"308-316","source":"Crossref","is-referenced-by-count":33,"title":["Tiagabine in Adult Patients With Generalized Anxiety Disorder"],"prefix":"10.1097","volume":"28","author":[{"given":"Mark H.","family":"Pollack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Tiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar H.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"suppl 8","key":"R2-9-20210128","first-page":"11","article-title":"The long-term clinical course of generalized anxiety disorder.","volume":"63","author":"Keller","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1185\/030079905X48401","article-title":"Benzodiazepines and anxiety disorders: a review for the practicing physician.","volume":"21","author":"Kaplan","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R4-9-20210128","first-page":"CD006115","article-title":"Azapirones for generalized anxiety disorder.","volume":"3","author":"Chessick","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-9-20210128","first-page":"CD003592","article-title":"Antidepressants for generalized anxiety disorder.","volume":"2","author":"Kapczinski","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 1","key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1017\/S1092852900006945","article-title":"World Council of Anxiety recommendations for the long-term treatment of generalized anxiety disorder.","volume":"8","author":"Allgulander","year":"2003","journal-title":"CNS Spectr"},{"issue":"suppl 2","key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.euroneuro.2006.04.004","article-title":"Therapeutic options: addressing the current dilemma.","volume":"16","author":"Dinan","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0447.2000.tb10947.x","article-title":"Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.","volume":"403","author":"Zohar","year":"2000","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0922-4106(94)90089-2","article-title":"Tiagabine, SKF 89976-A, CI-996, and NNC-711 are selective for the cloned GABA transporter GAT-1.","volume":"269","author":"Borden","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0014-2999(92)90748-S","article-title":"The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.","volume":"220","author":"Fink-Jensen","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/0269881103017002004","article-title":"GABA-ergic drugs: exit stage left, enter stage right.","volume":"17","author":"Ashton","year":"2003","journal-title":"J Psychopharmacol"},{"key":"R12-9-20210128","first-page":"21","article-title":"The role of GABA in anxiety disorders.","volume":"64","author":"Lydiard","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R13-9-20210128","first-page":"133","article-title":"The role of GABA in the pathophysiology and treatment of anxiety disorders.","volume":"37","author":"Nemeroff","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4088\/JCP.v66n1109","article-title":"The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study.","volume":"66","author":"Pollack","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"suppl 20","key":"R15-9-20210128","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4088\/JCP.v67n0511","article-title":"Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.","volume":"67","author":"Montgomery","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.jcp.0000084032.22282.ff","article-title":"A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.","volume":"23","author":"Feltner","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jad.2004.11.011","article-title":"Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials.","volume":"87","author":"Goodman","year":"2005","journal-title":"J Affect Disord"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4088\/JCP.v62n0508","article-title":"Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.","volume":"62","author":"Pollack","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/da.10146","article-title":"Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo-controlled, flexible-dose study.","volume":"19","author":"Davidson","year":"2004","journal-title":"Depress Anxiety"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.4088\/JCP.v67n1111","article-title":"Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram.","volume":"67","author":"Stein","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1176\/appi.ajp.161.9.1642","article-title":"Efficacy of sertraline in a 12-week trial for generalized anxiety disorder.","volume":"161","author":"Allgulander","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"suppl 11","key":"R23-9-20210128","first-page":"30","article-title":"Placebo response in generalized anxiety: its effect on the outcome of clinical trials.","volume":"58","author":"Schweizer","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"suppl 2","key":"R24-9-20210128","first-page":"14","article-title":"The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety.","volume":"66","author":"Roy-Byrne","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1056\/NEJMc055301","article-title":"Seizure activity and off-label use of tiagabine.","volume":"354","author":"Flowers","year":"2006","journal-title":"NEJM"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4088\/JCP.v64n1016","article-title":"Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.","volume":"64","author":"Rosenthal","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/10401230591002138","article-title":"An open-label study of tiagabine as augmentation therapy for anxiety.","volume":"17","author":"Schwartz","year":"2005","journal-title":"Ann Clin Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JCP.0b013e318172b45f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:01:55Z","timestamp":1786035715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200806000-00009"}},"subtitle":["Results From 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies"],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318172b45f","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}